The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

There is disclosed a composition and a method for the efficient delivery of a therapeutic RNAi-inducing nucleic acid to cells both in vitro and in vivo through specific formulations of a non viral delivery system using chitosans. Particularly, the composition contains a nucleic acid and a specific chitosan that has the following physico-chemical properties: a number-average molecular weight between 5 kDa and 200 kDa, a degree of deacetylation between 80% and 95% and a chitosan amine to nucleic acid phosphate ratio below 20.

There is disclosed a composition and a method for the efficient delivery of a therapeutic RNAi-inducing nucleic acid to cells both in vitro and in vivo through specific formulations of a non viral delivery system using chitosans. Particularly, the composition contains a nucleic acid and a specific chitosan that has the following physico-chemical properties: a number-average molecular weight between 5 kDa and 200 kDa, a degree of deacetylation between 80% and 95% and a chitosan amine to nucleic acid phosphate ratio below 20.

There is disclosed a composition and a method for the efficient delivery of a therapeutic RNAi-inducing nucleic acid to cells both in vitro and in vivo through specific formulations of a non viral delivery system using chitosans. Particularly, the composition contains a nucleic acid and a specific chitosan that has the following physico-chemical properties: a number-average molecular weight between 5 kDa and 200 kDa, a degree of deacetylation between 80% and 95% and a chitosan amine to nucleic acid phosphate ratio below 20.

Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, inhibiting disruption of the blood-brain barrier, inhibiting CNS contusion progression and improving post-contusion motor function, inhibiting microvascular impairment caused by endothelial cell swelling and fragmentation, inhibiting extravasation of blood into the brain parenchyma of a subject, inhibiting endothelial cell breakdown in a brain tissue, inhibiting extravasation of endovascular fluids into the brain's interstitium, decreasing vasogenic edema as measured by T2 flair magnetic resonance imaging, and decreasing matrix metalloprotease concentration in a CNS tissue, by administering a SUR1-TRPM4 channel inhibitor alone or in combination with one or more drugs or agents.

Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, inhibiting disruption of the blood-brain barrier, inhibiting CNS contusion progression and improving post-contusion motor function, inhibiting microvascular impairment caused by endothelial cell swelling and fragmentation, inhibiting extravasation of blood into the brain parenchyma of a subject, inhibiting endothelial cell breakdown in a brain tissue, inhibiting extravasation of endovascular fluids into the brain's interstitium, decreasing vasogenic edema as measured by T2 flair magnetic resonance imaging, and decreasing matrix metalloprotease concentration in a CNS tissue, by administering a SUR1-TRPM4 channel inhibitor alone or in combination with one or more drugs or agents.

Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, inhibiting disruption of the blood-brain barrier, inhibiting CNS contusion progression and improving post-contusion motor function, inhibiting microvascular impairment caused by endothelial cell swelling and fragmentation, inhibiting extravasation of blood into the brain parenchyma of a subject, inhibiting endothelial cell breakdown in a brain tissue, inhibiting extravasation of endovascular fluids into the brain's interstitium, decreasing vasogenic edema as measured by T2 flair magnetic resonance imaging, and decreasing matrix metalloprotease concentration in a CNS tissue, by administering a SUR1-TRPM4 channel inhibitor alone or in combination with one or more drugs or agents.

The present invention relates to the area of pharmaceutical compositions. More particularly, the present invention relates to a series of pharmaceutical compositions (PTM) containing phyto-polyphenols (P), clinical drugs with selective targets (T) and a metal ions (M) and the methods thereof for use in prevention and therapy of infectious diseases, neurodegenerative diseases, dementia, diabetes, obesity, metabolic syndromes, osteoporosis, cancers and/or chronic pain.

The present invention relates to the area of pharmaceutical compositions. More particularly, the present invention relates to a series of pharmaceutical compositions (PTM) containing phyto-polyphenols (P), clinical drugs with selective targets (T) and a metal ions (M) and the methods thereof for use in prevention and therapy of infectious diseases, neurodegenerative diseases, dementia, diabetes, obesity, metabolic syndromes, osteoporosis, cancers and/or chronic pain.

The present invention relates to a liquid pharmaceutical formulation of hypoglycaemic sulfonamide, intended for oral or ophthalmic administration. The present invention relates in particular to an oral formulation particularly suitable for paediatric use.